Halozyme Therapeutics (HALO) Stock Price, News & Analysis

+0.26 (+0.67%)
(As of 04/23/2024 ET)
Today's Range
50-Day Range
52-Week Range
557,947 shs
Average Volume
1.25 million shs
Market Capitalization
$4.95 billion
P/E Ratio
Dividend Yield
Price Target

Halozyme Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.86 Rating Score
36.7% Upside
$53.29 Price Target
Short Interest
6.28% of Float Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
0.71mentions of Halozyme Therapeutics in the last 14 days
Based on 17 Articles This Week
Insider Trading
Selling Shares
$1.20 M Sold Last Quarter
Proj. Earnings Growth
From $3.45 to $4.26 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.92 out of 5 stars

Medical Sector

17th out of 909 stocks

Biological Products, Except Diagnostic Industry

4th out of 155 stocks

HALO stock logo

About Halozyme Therapeutics Stock (NASDAQ:HALO)

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

HALO Stock Price History

HALO Stock News Headlines

top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
9 Analysts Have This To Say About Halozyme Therapeutics
3 Biotech Stocks to Buy in 2024
The 3 Best Biotech Stocks to Buy in Q2 2024
HALO Apr 2024 35.000 put
7 Biotech Stocks to Buy as Sector Rotation Ramps Up
I:RUT Mar 2024 Weekly 1905.000
TD Cowen Reaffirms Their Buy Rating on Halozyme (HALO)
3 Biotech Stocks for Sustainable Returns
See More Headlines
Receive HALO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Halozyme Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
7 Analysts


Net Income
$281.59 million
Pretax Margin


Sales & Book Value

Annual Sales
$829.25 million
Cash Flow
$3.22 per share
Book Value
$0.63 per share


Free Float
Market Cap
$4.97 billion

Social Links

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

  • Dr. Helen I. Torley M.B. Ch. B. (Age 61)
    M.R.C.P., President, CEO & Director
    Comp: $1.82M
  • Ms. Nicole LaBrosseMs. Nicole LaBrosse (Age 41)
    Senior VP & CFO
    Comp: $849.36k
  • Dr. Michael J. LaBarre Ph.D. (Age 60)
    Senior VP & Chief Technical Officer
    Comp: $843.89k
  • Mr. Mark Snyder Esq.
    Senior VP & Chief Legal Officer
  • Ms. Cortney Caudill M.B.A.
    Chief Operations Officer
  • Ms. Tram Bui
    Head of Investor Relations & Corporate Communications
  • Ms. Amy Marinne Fox
    Senior Vice President of Human Resources
  • Ms. Kristin Schwartzbauer
    Head of Quality
  • Mr. Gary Grote
    Chief Commercial Officer
  • Dr. Christopher Wahl M.B.A.
    M.D., Chief Business Officer

HALO Stock Analysis - Frequently Asked Questions

Should I buy or sell Halozyme Therapeutics stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Halozyme Therapeutics in the last year. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" HALO shares.
View HALO analyst ratings
or view top-rated stocks.

What is Halozyme Therapeutics' stock price target for 2024?

7 Wall Street research analysts have issued 1 year price objectives for Halozyme Therapeutics' stock. Their HALO share price targets range from $40.00 to $72.00. On average, they anticipate the company's stock price to reach $53.29 in the next twelve months. This suggests a possible upside of 36.7% from the stock's current price.
View analysts price targets for HALO
or view top-rated stocks among Wall Street analysts.

How have HALO shares performed in 2024?

Halozyme Therapeutics' stock was trading at $36.96 at the beginning of 2024. Since then, HALO stock has increased by 5.4% and is now trading at $38.97.
View the best growth stocks for 2024 here

When is Halozyme Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our HALO earnings forecast

How were Halozyme Therapeutics' earnings last quarter?

Halozyme Therapeutics, Inc. (NASDAQ:HALO) posted its quarterly earnings results on Tuesday, February, 20th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, missing the consensus estimate of $0.77 by $0.02. The biopharmaceutical company had revenue of $230.04 million for the quarter, compared to the consensus estimate of $235.25 million. Halozyme Therapeutics had a net margin of 33.96% and a trailing twelve-month return on equity of 248.20%.

What guidance has Halozyme Therapeutics issued on next quarter's earnings?

Halozyme Therapeutics issued an update on its FY 2024 earnings guidance on Tuesday, February, 20th. The company provided earnings per share guidance of 3.550-3.900 for the period, compared to the consensus EPS estimate of 3.510. The company issued revenue guidance of $915.0 million-$985.0 million, compared to the consensus revenue estimate of $961.1 million.

What is Helen Torley's approval rating as Halozyme Therapeutics' CEO?

12 employees have rated Halozyme Therapeutics Chief Executive Officer Helen Torley on Helen Torley has an approval rating of 75% among the company's employees.

What other stocks do shareholders of Halozyme Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Halozyme Therapeutics investors own include Xtrackers California Municipal Bond ETF (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Micron Technology (MU), Gilead Sciences (GILD), Athabasca Oil (ATH), NIC (EGOV), Allergan (AGN) and AbbVie (ABBV).

Who are Halozyme Therapeutics' major shareholders?

Halozyme Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Allspring Global Investments Holdings LLC (0.55%), Congress Asset Management Co. MA (0.32%), Hodges Capital Management Inc. (0.25%), Norden Group LLC (0.13%), AMI Asset Management Corp (0.11%) and Los Angeles Capital Management LLC (0.10%). Insiders that own company stock include Connie Matsui, Helen Torley, James M Daly, Jean-Pierre Bizzari, Jeffrey William Henderson, Matthew L Posard, Michael J Labarre and Nicole Labrosse.
View institutional ownership trends

How do I buy shares of Halozyme Therapeutics?

Shares of HALO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Halozyme Therapeutics have any subsidiaries?
The following companies are subsidiares of Halozyme Therapeutics: Halozyme Holdings Ltd., Halozyme Inc., Halozyme Switzerland GmbH, and Halozyme Switzerland Holdings GmbH.
Read More
This page (NASDAQ:HALO) was last updated on 4/23/2024 by Staff

From Our Partners